MetaADEDB 2.0 @ LMMD
eliglustat
(KUBARPMUNHKBIQ-VTHUDJRQSA-N)
Structure
SMILES
O[C@H]([C@H](C(=O)O)O)C(=O)O.CCCCCCCC(=O)N[C@@H]([C@@H](c1ccc2c(c1)OCCO2)O)CN1CCCC1.CCCCCCCC(=O)N[C@@H]([C@@H](c1ccc2c(c1)OCCO2)O)CN1CCCC1
Molecular Formula:
C50H78N4O14
Molecular Weight:
959.173
Log P:
5.3996
Hydrogen Bond Acceptor:
18
Hydrogen Bond Donor:
8
TPSA:
257.12
CAS Number(s):
928659-70-5
Synonym(s)
1.
eliglustat
2.
Cerdelga
3.
Genz-112638
4.
eliglustat tartrate
External Link(s)
MeSHC522917
PubChem Compound52918379
ChEBI83353
KEGGdr:D09894
Therapeutic Target DatabaseD0J8IJ
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Product dose omissionFAERS: 27US FAERS
2FatigueFAERS: 15US FAERS
3DyspepsiaFAERS: 14US FAERS
4NauseaFAERS: 12US FAERS
5DizzinessFAERS: 10US FAERS
6Memory impairmentFAERS: 10US FAERS
7ArthralgiaFAERS: 9US FAERS
8ConstipationFAERS: 9US FAERS
9Abdominal PainFAERS: 8US FAERS
10HeadacheFAERS: 8US FAERS
11VomitingFAERS: 7US FAERS
12Chest PainFAERS: 6US FAERS
13Drug dose omissionFAERS: 6US FAERS
14PalpitationsFAERS: 6US FAERS
15AnxietyFAERS: 5US FAERS
16AstheniaFAERS: 5US FAERS
17NasopharyngitisFAERS: 5US FAERS
18Oropharyngeal painFAERS: 5US FAERS
19PainFAERS: 5US FAERS
20Product use issueFAERS: 5US FAERS
21SinusitisFAERS: 5US FAERS
22Therapy cessationFAERS: 5US FAERS
23Bone painFAERS: 4US FAERS
24Drug ineffectiveFAERS: 4US FAERS
25Dry skinFAERS: 4US FAERS
26MalaiseFAERS: 4US FAERS
27Back PainFAERS: 3US FAERS
28ErythemaFAERS: 3US FAERS
29Feeling abnormalFAERS: 3US FAERS
30PruritusFAERS: 3US FAERS
31RetchingFAERS: 3US FAERS
32SyncopeFAERS: 3US FAERS
33TachycardiaFAERS: 3US FAERS
34Throat irritationFAERS: 3US FAERS
35ThrombocytopeniaFAERS: 3US FAERS
36TremorFAERS: 3US FAERS
37Chitotriosidase increasedFAERS: 2US FAERS
38CholecystitisFAERS: 2US FAERS
39DehydrationFAERS: 2US FAERS
40Disease ProgressionFAERS: 2US FAERS
41DiverticulitisFAERS: 2US FAERS
42FlatulenceFAERS: 2US FAERS
43Gastric ulcerFAERS: 2US FAERS
44GastritisFAERS: 2US FAERS
45Peripheral swellingFAERS: 2US FAERS
46PertussisFAERS: 2US FAERS
47Pulmonary EmbolismFAERS: 2US FAERS
48SomnolenceFAERS: 2US FAERS
49SplenomegalyFAERS: 2US FAERS
50Transaminases increasedFAERS: 2US FAERS
51Unevaluable eventFAERS: 2US FAERS
52Urinary tract infectionFAERS: 2US FAERS
53nervous system disorderFAERS: 2US FAERS
54AbasiaFAERS: 1US FAERS
55Abdominal discomfortFAERS: 1US FAERS
56AcneFAERS: 1US FAERS
57AphoniaFAERS: 1US FAERS
58Blood urine presentFAERS: 1US FAERS
59Bone marrow infiltrationFAERS: 1US FAERS
60BronchitisFAERS: 1US FAERS
61Cardiac FlutterFAERS: 1US FAERS
62Cardiac function test abnormalFAERS: 1US FAERS
63Cerebrovascular accidentFAERS: 1US FAERS
64Chest discomfortFAERS: 1US FAERS
65CholelithiasisFAERS: 1US FAERS
66Contraindicated product administeredFAERS: 1US FAERS
67CystitisFAERS: 1US FAERS
68CystFAERS: 1US FAERS
69DysarthriaFAERS: 1US FAERS
70Economic problemFAERS: 1US FAERS
71Electrocardiogram abnormalFAERS: 1US FAERS
72EructationFAERS: 1US FAERS
73Extra dose administeredFAERS: 1US FAERS
74Eye InfectionFAERS: 1US FAERS
75FlushingFAERS: 1US FAERS
76Hepatic enzyme decreasedFAERS: 1US FAERS
77Hip surgeryFAERS: 1US FAERS
78HypersomniaFAERS: 1US FAERS
79IleusFAERS: 1US FAERS
80Inappropriate schedule of drug administrationFAERS: 1US FAERS
81Incorrect dose administeredFAERS: 1US FAERS
82InfarctionFAERS: 1US FAERS
83InfectionFAERS: 1US FAERS
84Joint swellingFAERS: 1US FAERS
85Limb discomfortFAERS: 1US FAERS
86Maternal exposure during pregnancyFAERS: 1US FAERS
87Maternal exposure timing unspecifiedFAERS: 1US FAERS
88Middle insomniaFAERS: 1US FAERS
89Myocardial InfarctionFAERS: 1US FAERS
90NephrolithiasisFAERS: 1US FAERS
91NervousnessFAERS: 1US FAERS
92NeutropeniaFAERS: 1US FAERS
93Non-compaction cardiomyopathyFAERS: 1US FAERS
94OsteomyelitisFAERS: 1US FAERS
95OsteopeniaFAERS: 1US FAERS
96Pain of skinFAERS: 1US FAERS
97PancytopeniaFAERS: 1US FAERS
98Pathological fractureFAERS: 1US FAERS
99PetechiaeFAERS: 1US FAERS
100Pharyngeal polypFAERS: 1US FAERS
101Pregnancy of partnerFAERS: 1US FAERS
102PregnancyFAERS: 1US FAERS
103PresyncopeFAERS: 1US FAERS
104Productive CoughFAERS: 1US FAERS
105RadiculopathyFAERS: 1US FAERS
106Rash erythematousFAERS: 1US FAERS
107SneezingFAERS: 1US FAERS
108Stitch abscessFAERS: 1US FAERS
109Therapy changeFAERS: 1US FAERS
110ThrombosisFAERS: 1US FAERS
111TinnitusFAERS: 1US FAERS
112VasculitisFAERS: 1US FAERS
113Venous occlusionFAERS: 1US FAERS
114Weight decreasedFAERS: 1US FAERS
115White blood cell count decreasedFAERS: 1US FAERS
116Wound InfectionFAERS: 1US FAERS
117prostatitisFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.